Metastatic gastric cancer: 2nd-line cetuximab + mFOLFIRI shows promise

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Cetuximab and modified FOLFIRI (mFOLFIRI) appeared well tolerated and active as second-line treatment for patients with metastatic gastric cancer (MGC); low baseline plasma vascular endothelial growth factor (VEGF) levels were associated with better clinical outcomes.

Why this m...